Research Article Details
| Article ID: | A12775 |
| PMID: | 30292582 |
| Source: | Rev Gastroenterol Mex (Engl Ed) |
| Title: | Prevalence of hepatic steatosis and its relation to liver function tests and lipid profile in patients at medical check-up. |
| Abstract: | INTRODUCTION AND AIMS: Nonalcoholic fatty liver disease has now become a worldwide health problem, and its dramatic increase is due to the prevalence of diseases such as obesity, type 2 diabetes mellitus, and metabolic syndrome. The aim of our study was to publish the current prevalence of hepatic steatosis in a Mexican population undergoing routine medical check-up, as well as to analyze its relation to BMI, liver function tests, and lipid profile. MATERIALS AND METHODS: An observational, retrospective, cross-sectional study was conducted on patients that underwent medical check-up within the time frame of January 2011 and December 2015 at the Hospital San Javier. Patients included in the study were those with somatometry measurements (BMI), lipid profile, liver function tests, and abdominal ultrasound with a multi-frequency convex transducer. RESULTS: We found that 65% of the patients presented with overweight or obesity and there was a 49.19% prevalence of hepatic steatosis in the study population. That prevalence was more frequent in men and hepatic steatosis was strongly linked to an increase in triglycerides, AST, and GGT and a decrease in HDL. CONCLUSIONS: Establishing the technical aspects of the study was an important aid to having better correlation with and standardization of the accepted definitions, given that ultrasound is an adequate screening technique for an open population. Our results clearly showed a direct relation between hepatic steatosis and alterations in BMI, triglycerides, HDL, ALT, and GGT. |
| DOI: | 10.1016/j.rgmx.2018.05.007 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |